ReviewJournal of cellular and molecular medicine2022
Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome.
Review in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07104981 (Retrospective Evaluation of the Efficacy and Safety of Micronized Adipose Tissue Obtained With the Matrigen Device in the Treatment of Patients With Interstitial Cystitis), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retrospective Evaluation of the Efficacy and Safety of Micronized Adipose Tissue Obtained With the Matrigen Device in the Treatment of Patients With Interstitial Cystitis
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- Treatment of interstitial cystitis with intravesical instillation of recombinant human collagen type Ⅲ.The Canadian journal of urology · 2026Article
- Mesenchymal stem Cells and Extracellular Vesicles in Bladder Dysfunction: Mechanisms and Translational Perspectives.Stem cell reviews and reports · 2026Review
- Diagnostic Model Development for IC/BPS and Its Subtypes Using Clinical Indicators, Urinary Biomarkers, and Single-Cell Transcriptomic Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Exosomes in Benign Urological Disorders: From Molecular Biology to Clinical Perspectives.International journal of molecular sciences · 2026Review
- Transurethral Injection of Autologous Micronized Adipose Tissue for Refractory Interstitial Cystitis/Bladder Pain Syndrome: A Retrospective Pilot Study.Biomedicines · 2026Article
- Clinical Applications of Extracellular Vesicles: Promises and Pitfalls.International journal of molecular sciences · 2026Review
- Biomaterials and Nanomedicine for Mucosal Repair and Inflammation Control in Interstitial Cystitis/Bladder Pain Syndrome: An Extensive Review.International journal of nanomedicine · 2026Review
- Pilot Proteomic Analysis of Urinary Extracellular Vesicles Supports the "Toxic Urine Hypothesis" as a Vicious Cycle in Refractory IC/BPS Pathogenesis.International journal of molecular sciences · 2025Article
- The Model of Interstitial Cystitis for Evaluating New Molecular Strategies of Interstitial Regeneration in Humans.International journal of molecular sciences · 2024Review
- Mesenchymal stem cell transplantation plays a role in relieving cancer pain.Frontiers in pharmacology · 2024Review
- Adipose-derived stem cell exosomes act as delivery vehicles of microRNAs in a dog model of chronic hepatitis.Nanotheranostics · 2024Article
- Body fluid-derived stem cells - an untapped stem cell source in genitourinary regeneration.Nature reviews. Urology · 2023Review
- Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.Seminars in immunology · 2023Review
- New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome.BMB reports · 2022Review
- Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome.Journal of cellular and molecular medicine · 2022Review
- Round up.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is characterized by several symptoms of higher sensitivity of the lower urinary tract, such as bladder pain/discomfort, urgency, urinary frequency, pelvic pain and nocturia. Although the pathophysiology of IC/BPS is not fully understood, the hypothesis suggests that mast cell activation, glycosaminoglycan (GAG) layer defects, urothelium permeability disruption, inflammation, autoimmune disorder and infection are potential mechanisms. Mesenchymal stem cells (MSCs) have been proven to protect against tissue injury in IC/BPS by migrating into bladders, differentiating into key bladder cells, inhibiting mast cell accumulation and cellular apoptosis, inhibiting inflammation and oxidative stress, alleviating collagen fibre accumulation and enhancing tissue regeneration in bladder tissues. In addition, MSCs can protect against tissue injury in IC/BPS by secreting various soluble factors, including exosomes and other soluble factors, with antiapoptotic, anti-inflammatory, angiogenic and immunomodulatory properties in a cell-to-cell independent manner. In this review, we comprehensively summarized the current potential pathophysiological mechanisms and standard treatments of IC/BPS, and we discussed the potential mechanisms and therapeutic effects of MSCs and MSC-derived exosomes in alleviating tissue injury in IC/BPS models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.